Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice

This study demonstrates that bivalent S-EABR mRNA-LNP boosters, which encode engineered immunogens inducing virus-like particle budding, elicit superior and more diverse polyclass receptor-binding domain antibody responses against SARS-CoV-2 variants in pre-vaccinated mice compared to conventional boosters, suggesting a promising strategy for broader and more durable protection.

The Gist

The Big Picture: Fighting a Shapeshifting Enemy

Imagine the SARS-CoV-2 virus as a master thief who keeps changing his disguise (the "variants" like Omicron, BA.5, XBB, etc.). Our current vaccines are like "Wanted Posters" showing the thief's original face. When the thief changes his disguise, the police (our immune system) have a harder time recognizing him.

To keep up, scientists usually have to print new "Wanted Posters" (updated boosters) every few months. This is slow, expensive, and often lags behind the thief's changes.

This paper introduces a new strategy: Instead of just showing a picture of the thief, the new vaccine creates a 3D, moving, multi-faced hologram of the thief. This hologram is so convincing and complex that it trains the immune system to recognize the thief even when he changes his disguise.

---

The Problem: "Imprinting" and the Old Photos

The study looked at mice that had already been vaccinated with the original "Wuhan" version of the vaccine. These mice had a strong memory of the original thief.

When the researchers gave them a standard booster (just a new photo of the thief), the mice's immune systems mostly just refreshed their memory of the original face. They didn't learn enough about the new disguises (Omicron variants). This is called "immune imprinting"—the immune system gets stuck looking at the first photo it ever saw and ignores the new ones.

The Solution: The "EABR" Hologram

The researchers tested a new technology called EABR.

• Standard Vaccine: Imagine a billboard showing a flat, 2D photo of the thief.
• EABR Vaccine: Imagine a floating, 3D virus-like particle (a "Virus-Like Particle" or eVLP) that buds off from the cell, carrying the thief's face on its surface. It's like a tiny, floating balloon covered in the thief's face, floating right next to the billboard.

This "floating balloon" approach makes the immune system pay much more attention. It's like the difference between looking at a photo in a book vs. seeing a life-sized, moving model of the person right in front of you.

The Experiment: The "Bivalent" Mix

The researchers tested four groups of mice to see which booster worked best against the new disguises (Omicron variants):

1. The Old Photo: A standard booster with just the original Wuhan virus.
2. The Old Hologram: A booster with the original Wuhan virus, but using the new "floating balloon" (EABR) tech.
3. The Two-Photo Mix: A standard booster with both the original Wuhan face and a new BA.5 face.
4. The Ultimate Mix: A booster with both faces, but using the "floating balloon" (EABR) tech.

The Results:

• Group 4 (The Ultimate Mix) was the clear winner. It didn't just produce more antibodies; it produced smarter antibodies.
• While the other groups mostly made antibodies that only recognized the "top" of the thief's face (which the thief changes easily), Group 4 made antibodies that recognized the entire face, including the parts the thief rarely changes.
• This "polyclass" response means the immune system has a diverse army of weapons, making it much harder for the virus to escape.

The Secret Sauce: The "Hybrid" Mask

The paper also discovered a fascinating biological trick. When the body makes the "Ultimate Mix" (Group 4), the cells accidentally mix the original Wuhan face and the new BA.5 face together on the same floating balloon.

Think of it like a hybrid mask that has one eye from the old thief and one eye from the new thief.

• When the immune system sees this hybrid mask, it realizes, "Hey, these two faces are related!"
• This forces the immune system to activate "cross-reactive" soldiers—special agents trained to spot the similarities between the old and new disguises.
• The researchers used high-tech microscopes (Cryo-EM) to prove these hybrid masks actually exist.

Why This Matters

1. Broader Protection: This approach creates a "Swiss Army Knife" immune response. Instead of needing a new key for every new lock (variant), this vaccine creates a master key that fits many locks.
2. Less Frequent Boosters: Because the immune response is so broad and deep, we might not need to update the vaccine as often.
3. Future-Proofing: This technology could be used for other rapidly changing viruses (like the flu), giving us a way to stay ahead of the shapeshifters without constantly playing catch-up.

The Bottom Line

This paper shows that by changing how we deliver the vaccine (using floating 3D particles instead of just flat instructions), we can trick the immune system into learning a much more complete lesson. Even if the virus changes its disguise, our immune system will be ready because it learned to recognize the thief's true nature, not just his current outfit.

Technical Summary

1. Problem Statement

Despite the success of mRNA vaccines during the COVID-19 pandemic, their long-term efficacy is limited by two main factors:

• Waning Immunity: Antibody levels decline over time, necessitating frequent boosters.
• Viral Evolution: The emergence of SARS-CoV-2 variants (particularly Omicron subvariants like BA.1, BA.5, BQ.1.1, and XBB.1) with significant mutations in the Spike (S) protein allows them to evade neutralizing antibodies generated by ancestral vaccines.
• Immune Imprinting (Original Antigenic Sin): In pre-vaccinated individuals, subsequent boosters often reactivate pre-existing memory B cells specific to the ancestral strain rather than generating de novo responses against new variants. This limits the breadth and potency of neutralization against emerging variants.
• Manufacturing Lag: The time required to develop, test, and approve updated bivalent or multivalent boosters often lags behind viral evolution.

The study aims to address these challenges by evaluating a novel EABR (ESCRT- and ALIX-binding region) mRNA vaccine platform as a booster strategy in pre-vaccinated mice. This platform is designed to induce the budding of enveloped virus-like particles (eVLPs), potentially overcoming immune imprinting and enhancing cross-reactive B cell activation.

2. Methodology

The researchers conducted a preclinical study using BALB/c mice that had been previously primed and boosted with a conventional monovalent Wuhan-Hu-1 (Wu1) S mRNA-LNP vaccine.

• Experimental Design:
  • Prime/Boost: Mice received two doses of conventional Wu1 S mRNA-LNP on Days 0 and 28.
  • Booster (Day 230): Mice were divided into four cohorts (n=10 each) receiving different boosters:
    1. Monovalent Conventional: Wu1 S mRNA-LNP.
    2. Monovalent EABR: Wu1 S-EABR mRNA-LNP (induces eVLPs).
    3. Bivalent Conventional: Mix of Wu1 S and BA.5 S mRNA-LNP.
    4. Bivalent EABR: Mix of Wu1 S-EABR and BA.5 S-EABR mRNA-LNP (induces eVLPs displaying both variants).
• Immunogenicity Assays:
  • ELISA: Measured binding antibodies against S trimers (Wu1, BA.5, BQ.1.1, XBB.1) and RBDs at multiple timepoints.
  • Pseudovirus Neutralization: Measured ID50 titers against Wu1, BA.1, BA.5, BQ.1.1, and XBB.1 pseudoviruses.
  • Antibody Depletion: Sera from bivalent boosters were depleted of Wu1 RBD-binding antibodies to assess the contribution of cross-neutralizing vs. strain-specific antibodies.
• Epitope Mapping (Deep Mutational Scanning - DMS):
  • Yeast display libraries of Wu1 and XBB.1.5 RBDs were used to map polyclonal antibody escape profiles.
  • Polyclass Definition: Profiles with low total escape peaks (<0.5) across all sites were classified as "polyclass," indicating diverse targeting of multiple epitope classes (Class 1–5).
• Structural Biology (Cryo-EM):
  • Soluble heterotrimers (HT2: Wu1/BA.1; HT3: Wu1/BA.1/Delta) were engineered and purified to test if co-expression of different S variants leads to heterotrimer formation.
  • Cryo-EM was used to visualize the structure of these heterotrimers and assess if they maintain native conformation.

3. Key Contributions

• EABR Platform Validation in Pre-Immune Context: This is the first study to demonstrate that the EABR mRNA platform, which previously showed superiority in naïve mice, also enhances booster responses in mice with pre-existing immunity.
• Synergy of Bivalency and eVLPs: The study identifies that combining bivalent immunogens (Wu1 + BA.5) with the EABR eVLP mechanism yields the most potent and broad immune response, outperforming both monovalent and conventional bivalent boosters.
• Mechanistic Insight into Heterotrimers: The authors provide the first structural evidence (via Cryo-EM) that co-expression of ancestral and variant S proteins leads to the formation of S heterotrimers. They hypothesize that these heterotrimers facilitate intra-S crosslinking (binding of a single IgG to two RBDs on the same trimer), which may drive the activation of cross-reactive B cells.
• Polyclass Induction: The bivalent EABR booster uniquely induced a "polyclass" antibody response, targeting diverse RBD epitope classes simultaneously, rather than focusing solely on immunodominant epitopes.

4. Key Results

• Neutralizing Antibody Titers:
  • The Bivalent S-EABR mRNA-LNP booster elicited the highest neutralizing titers against all Omicron subvariants (BA.1, BA.5, BQ.1.1, XBB.1).
  • Against BA.5, the Bivalent EABR booster induced a 67-fold increase in neutralization compared to baseline (Day 154), significantly outperforming the conventional monovalent booster (6.3-fold increase).
  • The Bivalent EABR booster induced robust neutralizing titers (ID50 > 1:100) in 7 out of 10 mice against BQ.1.1 and 6 out of 10 against XBB.1, whereas the conventional monovalent booster only achieved this in 2–3 mice.
• Epitope Diversity (DMS):
  • Conventional/Monovalent Boosters: Elicited responses primarily targeting immunodominant Class 1/2 epitopes (Wu1) or Class 5 epitopes (XBB.1), showing "escape peaks" indicative of focused, less diverse responses.
  • Bivalent S-EABR Booster: Elicited polyclass responses (flat DMS profiles) against both Wu1 and XBB.1.5 RBDs. 4 out of 5 mice in this cohort showed polyclass profiles against Wu1, suggesting balanced targeting of multiple epitope classes.
• Role of Cross-Neutralization:
  • Depletion of Wu1 RBD-binding antibodies from bivalent booster sera resulted in a massive drop (17–36 fold) in BA.5 neutralization, indicating that the enhanced response is largely driven by cross-reactive antibodies rather than de novo strain-specific antibodies.
• Structural Findings:
  • Cryo-EM confirmed that soluble Wu1/BA.1 and Wu1/BA.1/Delta heterotrimers form successfully and retain the native "all-down" and "one-up" conformational states of the S trimer.
  • This supports the hypothesis that bivalent mRNA immunizations promote heterotrimerization, potentially enabling intra-S crosslinking to activate cross-reactive B cells.

5. Significance and Implications

• Overcoming Immune Imprinting: The study suggests that the EABR platform, particularly in a bivalent format, can break through immune imprinting to elicit broader, more diverse antibody responses in pre-vaccinated populations.
• Future Vaccine Design: The findings support the development of bivalent or multivalent EABR mRNA boosters as a strategy to confer durable protection against rapidly evolving viruses. The ability to induce polyclass responses reduces the likelihood of viral escape, as the virus would need to mutate multiple conserved epitope classes simultaneously.
• Mechanistic Innovation: The discovery of S heterotrimer formation and its potential role in intra-S crosslinking offers a new mechanistic target for vaccine design. It suggests that the physical presentation of antigens (e.g., on eVLPs or as heterotrimers) is as critical as the antigen sequence itself for driving cross-reactive immunity.
• Pandemic Preparedness: This platform could reduce the need for frequent, variant-specific updates by providing a "broad-spectrum" booster that maintains efficacy against current and future variants.

Limitations Noted: The study used older variants (BA.5, BQ.1.1) due to the timeline of the research; future work is needed to test against currently circulating variants (e.g., JN.1). Additionally, while the polyclass response was observed, the translation to in vivo protection against severe disease in humans requires further clinical investigation.